Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5…
10 analysts rate ALMS Buy on consensus.
Consensus price target: $39.40 (+603.57% upside from $5.60)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Schroer John R. Chief Financial Officer | Nov 2, 2026 | Sale | 794 | $5.18K |
| Hardiman Roy C. Chief Business & Strategy Ofcr | Nov 2, 2026 | Sale | 652 | $4.25K |
| Bradley Mark Christopher Chief Development Officer | Nov 2, 2026 | Sale | 623 | $4.06K |
| Drappa Jorn Chief Medical Officer | Nov 2, 2026 | Sale | 593 | $3.87K |
| Pangali Sanam Chief Legal Officer | Nov 2, 2026 | Sale | 332 | $2.16K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $24.05M | — | $-243.33M |
| 2024 | $0 | — | $-294.23M |
| 2023 | $0 | — | $-154.99M |
Stock data for ALMS: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics